Photodynamic effects of toluidine blue on human oral keratinocytes and fibroblasts and Streptococcus sanguis evaluated in vitro

Background and Objective Some oral bacteria are susceptible to killing by red light after their sensitization with toluidine blue O (TBO). The photochemotherapy of periodontal disease in vivo would require a therapeutic window where bacteria could be killed without adjacent normal tissue damage. Stu...

Full description

Saved in:
Bibliographic Details
Published in:Lasers in surgery and medicine Vol. 18; no. 3; pp. 253 - 259
Main Authors: Soukos, Nikolaos S., Wilson, Michael, Burns, Tracy, Speight, Paul M.
Format: Journal Article
Language:English
Published: New York John Wiley & Sons, Inc 1996
Wiley-Liss
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and Objective Some oral bacteria are susceptible to killing by red light after their sensitization with toluidine blue O (TBO). The photochemotherapy of periodontal disease in vivo would require a therapeutic window where bacteria could be killed without adjacent normal tissue damage. Study Design/Materials and Methods The laser‐induced effects of TBO on normal human gingival keratinocytes and fibroblasts have been studied in vitro. For the assessment of viability, the CellTiter 96™ AQueous Non‐Radioactive Cell Proliferation Assay was used. Results TBO was cytotoxic at low concentrations (5.0 μg/ml). Sensitization of keratinocytes and fibroblasts with 2 and 5.0 μg/ml TBO, respectively, for 5 min and exposure to light from a 7.3 mW Helium/Neon (HeNe) laser for up to 2 min (0.876J) did not reduce cell viability. However, killing of Streptococcus sanguis was achieved following exposure to HeNe light for 75 sec (0.547J) in the presence of TBO at a concentration of 2.5 μg/ml. Conclusion The development of a system for the lethal photosensitization of bacteria responsible for periodontal disease may be possible. © 1996 Wiley‐Liss, Inc.
Bibliography:istex:A54F8ED1BFAAAB841175740FC8A3648085AFD63D
ark:/67375/WNG-TKMMGXVH-D
ArticleID:LSM6
Zila Pharmaceutical
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0196-8092
1096-9101
DOI:10.1002/(SICI)1096-9101(1996)18:3<253::AID-LSM6>3.0.CO;2-R